Global Atrial Fibrillation (AF) Market to Grow at a CAGR Of 11.62% to Forecast 2020

Global Atrial Fibrillation market was $7.2 billion in 2015 and expected to grow to $12.5 billion by 2020 with and compound annual growth rate of 11.62%.

PUNE, INDIA , November 16, 2016 /EINPresswire.com/ -- Global Atrial Fibrillation Market

The Atrial Fibrillation-Market Insights & Drugs Sales Forecast (AF) -2020 report provides an overview of the disease, epidemiology and global market trends for the seven major markets ie: United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. According to DelveInsight, Global Atrial Fibrillation market was $7.2 billion in 2015 and expected to grow to $12.5 billion by 2020 with and compound annual growth rate (CAGR) of 11.62%.

Try Sample Report @ https://www.wiseguyreports.com/sample-request/476536-atrial-fibrillation-market-insights-drugs-sales-forecast-af-2020

Coagulation is an important phenomenon of body to stop external bleeding but when clots are formed in blood vessels, it can be lethal. Blood clots in arteries can lead to heart attack and when formed in the blood vessels of brain can lead to stroke. Thus, anticoagulants are used to prevent the formation of blood clots in the body. Anticoagulants are proved to be a beneficial medication for the treatment of Atrial fibrillation, Deep Vein Thrombosis, Pulmonary Embolism and Stroke.

Key Coverage and Benefits:

The report will help in developing business strategies by understanding the trends shaping and driving the global Atrial Fibrillation (AF) market.
• Identifying patient populations in the global Atrial Fibrillation (AF) market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the best opportunities for Atrial Fibrillation (AF) therapeutics in each of the markets covered.
• To understand the future market competition in the global Atrial Fibrillation (AF) therapeutics market and Insightful review of the key market drivers and barriers.
Access Complete Report @ https://www.wiseguyreports.com/reports/476536-atrial-fibrillation-market-insights-drugs-sales-forecast-af-2020

Scope of the Report:

• Report covers the disease overview including etiology, path physiology, symptoms, diagnosis, disease management and current treatment options.
• Marketed information including available prescription drugs, its patent and exclusivity details followed by drug sales till 2018.
• The Report also covers the detailed global historical and forecasted epidemiological data covering United States, EU5, Japan and rest of the word from 2015-2020.
• It also provides Atrial fibrillation (AF) for United States, EU5 and Japan from 2015 and forecasted Market to 2020.

Executive Summary
Market Share of Anticoagulants in 2015 and 2020
Worldwide Market Share of Anticoagulants in 2015
Worldwide Market Share of Anticoagulants in 2020
Chapter 1 Anticoagulants Introduction
Warfarin
Low Molecular Weight Heparins
New Oral Anticoagulants (NOAC)
Chapter 2 Atrial Fibrillation
Disease Overview
Epidemiology of Atrial Fibrillation
Treatment Landscape
Treatment Algorithm
Treatment Goals
Treatment Details
Chapter 3 Key Marketed Anticoagulants
Novel Oral Anticoagulants Comparison
Reversal Agents (Antidotes)
Chapter 4 Anticoagulants Market Assessment by AF
Key Findings
Global Anticoagulants Market Sales by Atrial Fibrillation (AF)
Global Anticoagulants Market Share (%) in Atrial Fibrillation
Chapter 5 United States Anticoagulants Market Assessment by AF
Key Findings
United States Anticoagulants Market Sales by Atrial Fibrillation
United States Anticoagulants Market Share (%) in Atrial Fibrillation
Chapter 6 Europe 5 Anticoagulants Market Assessment by AF
Key Findings
Europe 5 Anticoagulants Market Sales by Atrial Fibrillation
Europe 5 Anticoagulants Market Share (%) in Atrial Fibrillation
Chapter 7 Japan Anticoagulants Market Assessment by AF
Key Findings
Japan Anticoagulants Market Sales by Atrial Fibrillation
Japan Anticoagulants Market Share (%) in Atrial Fibrillation
Chapter 8 Xarelto (rivaroxaban) Drug Profile
Product Profile
Advantages & Disadvantages
Efficacy of Xarelto
Safety of Xarelto
Side effects of Drugs
Cost of Therapy
Global Drug Sales
Xarelto Historical Sales and Forecasted Sales (2011-2020)
Global Drug Sales by indication
Xarelto Historical Sales and Forecasted Sales (2011-2020) by AF
Clinical Trials Information
SWOT Analysis of Xarelto
Chapter 9 Pradaxa (dabigatran etexilate mesylate) Drug Profile
Product Profile
Advantages & Disadvantages
Efficacy of Pradaxa
Safety of Pradaxa
Side effects of Drugs
Cost of Therapy
Global Drug Sales
Pradaxa Historical Sales and Forecasted Sales (2011-2020)
Global Drug Sales by indication
Pradaxa Historical Sales and Forecasted Sales (2011-2020) by AF
Clinical Trial Information
SWOT Analysis of Pradaxa
Chapter 10 Eliquis(Apixaban) Drug Profile
Product Profile
Advantages & Disadvantages
Efficacy and Safety of Eliquis
Side effects of Eliquis
Cost of Therapy
Global Drug Sales
Eliquis Historical Sales and Forecasted Sales (2011-2020)
Global Drug Sales by indication
Eliquis Historical Sales and Forecasted Sales (2011-2020) by AF
Clinical Trial Information
SWOT Analysis of Eliquis
Chapter 11 Savaysa (edoxaban tosylate) Drug Profile
Product Profile
Advantages & Disadvantages
Efficacy of Savaysa
Safety of Savaysa
Side Effects of Savaysa
Cost of Therapy
Global Drug Sales
Savaysa Historical Sales and Forecasted Sales (2011-2020)
Global Drug Sales by indication
Savaysa Historical Sales and Forecasted Sales (2011-2020) by AF
Clinical Trial Information
SWOT Analysis of Savaysa
Chapter 12 Market Drivers and Constraints
Factors Driving the Market Growth
Factors Constraining the Market Growth
Consulting Services
Disclaimer
About DelveInsight

Purchase Report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=476536

For more information or any query mail at sales@wiseguyreports.com

Contact Us:
Norah Trent
+1 646 845 9349 / +44 208 133 9349
Follow on LinkedIn: https://www.linkedin.com/company/wise-guy-research-consultants-pvt-ltd-?trk=biz-companies-cym

Norah Trent
wiseguyreports
+1 646 845 9349 / +44 208 133 9349
email us here